ERBB2 and breast cancer: Collectively, HER2 knockdown significantly induced G1 phase arrest, decreased the expression of Cyclin D1 and CDK4, and enhanced the inhibitory effect of CDK4/6 inhibitor combined with endocrine therapy on HR+/HER2-low breast cancer cells.